Longitudinal analyses show lengthening of visual evoked potential latency and reductions in amplitude over time in stable disease.
Neuromyelitis optica (NMO) spectrum disorder (SD) is considered a relapsing-remitting disease, in that the disease is stable between exacerbations. However, some evidence has suggested possible subclinical activity between exacerbations. The German NMO Study Group retrospectively analyzed 203 eyes of 102 patients, with a median of 3 measurements of visual evoked potentials (VEPs) during a median 32 months of follow-up.
Optic neuritis (ON) had occurred in 118 eyes at least once during the disease. For eyes without ON during the observation period, the annual rate of change in P100 latency was 1.951 ms for eyes with follow-up of at least 3 months and 1.768 ms with follow-up of at least 12 months. A 1 standard-deviation reduction was observed i…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)